Wyeth-Ayerst/Elan Naprelan label includes data suggesting reduced GI side effects, but no explicit claim.
Executive Summary
WYETH-AYERST/ELAN NAPRELAN PHARMACY AVAILABILITY SET FOR APRIL following FDA's Jan. 5 approval of the once-daily version of naproxen sodium. The new formulation employs Elan's IPDAS system to deliver the nonsteroidal anti-inflammatory drug naproxen, the active ingredient in Roche's Naprosyn/Anaprox. Wyeth-Ayerst will market the drug under a July agreement with Elan. The naproxen ingredient accounts for about 20% of NSAID prescriptions, the firms said.